Bank of New York Mellon’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.9M | Sell |
407,840
-46,223
| -10% | -$1.49M | ﹤0.01% | 1770 |
|
|
2026
Q1 | $14.8M | Sell |
454,063
-20,558
| -4% | -$661K | ﹤0.01% | 1703 |
|
|
2025
Q4 | $16.7M | Sell |
474,621
-25,165
| -5% | -$892K | ﹤0.01% | 1637 |
|
|
2025
Q3 | $13.1M | Buy |
499,786
+57,111
| +13% | +$1.7M | ﹤0.01% | 1780 |
|
|
2025
Q2 | $11.7M | Sell |
442,675
-75,623
| -15% | -$1.99M | ﹤0.01% | 1814 |
|
|
2025
Q1 | $12.5M | Buy |
518,298
+55,334
| +12% | +$1.75M | ﹤0.01% | 1745 |
|
|
2024
Q4 | $18.6M | Buy |
462,964
+41,400
| +10% | +$2.36M | ﹤0.01% | 1608 |
|
|
2024
Q3 | $26.7M | Buy |
421,564
+14,308
| +4% | +$839K | 0.01% | 1417 |
|
|
2024
Q2 | $21.6M | Buy |
407,256
+58,763
| +17% | +$3.85M | ﹤0.01% | 1530 |
|
|
2024
Q1 | $28.6M | Buy |
348,493
+10,785
| +3% | +$480K | 0.01% | 1374 |
|
|
2023
Q4 | $6.28M | Buy |
337,708
+7,861
| +2% | +$103K | ﹤0.01% | 2251 |
|
|
2023
Q3 | $3.65M | Sell |
329,847
-8,290
| -2% | -$119K | ﹤0.01% | 2485 |
|
|
2023
Q2 | $5.48M | Buy |
338,137
+196,368
| +139% | +$4.11M | ﹤0.01% | 2276 |
|
|
2023
Q1 | $2.36M | Sell |
141,769
-16,517
| -10% | -$171K | ﹤0.01% | 2708 |
|
|
2022
Q4 | $1.49M | Buy |
158,286
+54,142
| +52% | +$242K | ﹤0.01% | 3001 |
|
|
2022
Q3 | $284K | Sell |
104,144
-1,640
| -2% | -$5.37K | ﹤0.01% | 3864 |
|
|
2022
Q2 | $306K | Sell |
105,784
-219,964
| -68% | -$544K | ﹤0.01% | 3866 |
|
|
2022
Q1 | $977K | Buy |
325,748
+67,835
| +26% | +$243K | ﹤0.01% | 3333 |
|
|
2021
Q4 | $1.19M | Sell |
257,913
-8,439
| -3% | -$47.3K | ﹤0.01% | 3281 |
|
|
2021
Q3 | $1.67M | Buy |
266,352
+16,191
| +6% | +$100K | ﹤0.01% | 3096 |
|
|
2021
Q2 | $1.5M | Sell |
250,161
-49,120
| -16% | -$292K | ﹤0.01% | 3179 |
|
|
2021
Q1 | $1.89M | Sell |
299,281
-496
| -0.2% | -$3.49K | ﹤0.01% | 2953 |
|
|
2020
Q4 | $1.69M | Sell |
299,777
-12,259
| -4% | -$74.3K | ﹤0.01% | 2943 |
|
|
2020
Q3 | $1.82M | Sell |
312,036
-2,646
| -0.8% | -$18.2K | ﹤0.01% | 2721 |
|
|
2020
Q2 | $2.27M | Sell |
314,682
-486
| -0.2% | -$3.23K | ﹤0.01% | 2608 |
|
|
2020
Q1 | $1.48M | Buy |
315,168
+3,875
| +1% | +$23.8K | ﹤0.01% | 2714 |
|
|
2019
Q4 | $2.5M | Buy |
311,293
+24,963
| +9% | +$182K | ﹤0.01% | 2686 |
|
|
2019
Q3 | $1.97M | Sell |
286,330
-82,672
| -22% | -$614K | ﹤0.01% | 2764 |
|
|
2019
Q2 | $3.06M | Buy |
369,002
+49,027
| +15% | +$419K | ﹤0.01% | 2574 |
|
|
2019
Q1 | $3.18M | Sell |
319,975
-67,064
| -17% | -$561K | ﹤0.01% | 2548 |
|
|
2018
Q4 | $2.96M | Buy |
387,039
+1,555
| +0.4% | +$18.6K | ﹤0.01% | 2548 |
|
|
2018
Q3 | $6.71M | Buy |
385,484
+39,455
| +11% | +$470K | ﹤0.01% | 2257 |
|
|
2018
Q2 | $3.28M | Buy |
346,029
+320,731
| +1,268% | +$2.13M | ﹤0.01% | 2592 |
|
|
2018
Q1 | $110K | Buy |
+25,298
| New | +$140K | ﹤0.01% | 4046 |
|
Other funds holding VKTX
Bank of New York Mellon's VKTX Position: Q2 2026 in Review
Bank of New York Mellon reduced its Viking Therapeutics (VKTX) stake by 10% in Q2 2026, selling an estimated $1.49M and leaving 407,840 shares worth $15.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1770.
Bank of New York Mellon first reported a position in VKTX in Q1 2018 and has held it in 34 quarters since. The position peaked at $28.6M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- Bank of New York Mellon held 407,840 shares of Viking Therapeutics worth $15.9M as of Q2 2026.
- Bank of New York Mellon sold 46,223 Viking Therapeutics shares in Q2 2026, an estimated $1.49M.
- Viking Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1770 holding.
- Bank of New York Mellon first reported a position in Viking Therapeutics in Q1 2018 and has held it in 34 quarters since.
- Bank of New York Mellon's Viking Therapeutics position peaked at $28.6M in Q1 2024.
- 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.